415 Capital

Supira Medical, Inc. develops a percutaneous ventricular assist device (pVAD) for use in high-risk patients undergoing interventional procedures. Its solution is a high-flow percutaneous pVAD for high risk PCI and cardiogenic shock for patients requiring temporary mechanical support during coronary interventions. The company’s solution is placed to provide temporary mechanical support, assisting the native pumping action of the heart and enabling patients to undergo necessary interventional procedures. Supira Medical, Inc. was formerly known as Lumenblation Medical, Inc. and changed its name to Supira Medical, Inc. in March 2016. The company was incorporated in 2012 and is based in Campbell, California.

DistalMotion Sàrl, founded in 2012 and headquartered in Lausanne, Switzerland, specializes in developing medical devices for minimally invasive surgeries. The company focuses on creating surgical robotic technology that simplifies surgical processes, specifically in dissection and suturing. Its innovative robotic device enhances laparoscopic procedures in the abdominal cavity, allowing healthcare professionals to deliver improved patient care. By bridging the gap between surgical robotics and traditional laparoscopy, DistalMotion aims to transform the landscape of minimally invasive surgery.

Aktiia SA, founded in 2018 and based in Neuchâtel, Switzerland, specializes in the development and manufacture of a blood pressure monitoring device. The company's flagship product is a smart bracelet equipped with optical sensors that continuously tracks users' systolic and diastolic blood pressure throughout the day and night. This data is accessible via an intuitive mobile app, allowing users to monitor their health conveniently. The bracelet's measurements are supported by clinically validated software algorithms, ensuring accuracy and reliability. The Aktiia platform also enables users to log their readings for personal use or share them with healthcare professionals. Through its innovative approach, Aktiia aims to empower individuals to better understand and manage their blood pressure, addressing a critical health concern effectively.

cardiac implant to improve cardiac function in patients with heart failure and/or functional mitral regurgitation.

CorFlow Therapeutics is a medtech startup focused on developing innovative technologies for the diagnosis and treatment of microvascular obstructions (MVO) in patients experiencing severe heart attacks. The company has created a controlled flow infusion system that measures the degree of MVO through a proprietary concept known as dynamic microvascular resistance. This system provides interventional cardiologists with critical data that can be compared to post-procedure contrast-enhanced magnetic resonance imaging. By enabling accurate diagnosis and treatment of MVO, CorFlow aims to reduce both short- and long-term complications in heart attack patients, addressing significant unmet medical needs in cardiovascular care.

Moray Medical specializes in developing advanced robotic delivery systems for structural heart therapies, particularly focusing on edge-to-edge valve leaflet repair for patients with leaky heart valves. The company aims to enhance the quality of life for individuals suffering from this condition by offering innovative solutions that enable cardiologists to perform mitral valve clip therapies more safely and cost-effectively. Moray Medical's technology features a compact, reusable fluid-drive system that allows precise movement of flexible delivery catheters, facilitated by a digital interface akin to operating a computer cursor. This approach streamlines the treatment process, making life-saving heart valve therapies more accessible to a greater number of patients.

Supira Medical, Inc. develops a percutaneous ventricular assist device (pVAD) for use in high-risk patients undergoing interventional procedures. Its solution is a high-flow percutaneous pVAD for high risk PCI and cardiogenic shock for patients requiring temporary mechanical support during coronary interventions. The company’s solution is placed to provide temporary mechanical support, assisting the native pumping action of the heart and enabling patients to undergo necessary interventional procedures. Supira Medical, Inc. was formerly known as Lumenblation Medical, Inc. and changed its name to Supira Medical, Inc. in March 2016. The company was incorporated in 2012 and is based in Campbell, California.